Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Jennifer A. Foltz(The University of Texas MD Anderson Cancer Center), Todd A. Fehniger(Washington University in St. Louis)
Cited by 0
Related Papers
Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells
|The Journal of Experimental Medicine|2001|365
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
|Journal of Clinical Investigation|2017|311
NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells
|Frontiers in Immunology|2016|47